Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma

Autologous CD19-targeted chimeric antigen receptor (CAR) T cell therapy has demonstrated the ability to produce durable remissions in patients with relapsed or refractory large B cell lymphoma (LBCL). There are currently 3 commercially available CAR T products for LBCL: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and the recently approved lisocabtagene maraleucel [1-3]. In the pivotal ZUMA-1 trial of axi-cel, 83% of patients had an objective response, and 39% had an ongoing response at a median follow-up of 27.1 months [4].

Source: Biology of Blood and Marrow Transplantation - May 29, 2021 Category: Hematology Authors: Albert Cortes, Ariel Perez, Christina Bachmeier, Rahul Mhaskar, Julio C. Chavez, Bijal Shah, Taiga Nishihori, Farhad Khimani, Aleksandr Lazaryan, Marco L. Davila, Frederick L. Locke, Michael D. Jain Source Type: research